Inactive Instrument

Enzymatica AB Share Price Nasdaq Stockholm

SE0003943620

Analysts' recommendations: Enzymatica AB

19/07/24	Penser lowers motivated value for Enzymatica - raises required return to reflect risk	FW
26/04/24	Redeye lowers motivated value for Enzymatica to SEK 5.5 (6.0)	FW
20/02/24	Penser lowers Enzymaticas' motivated value	FW
08/11/23	Penser lowers motivated value for Enzymatica	FW
08/11/23	Redeye lowers motivated value for Enzymatica to SEK 6.0 (6.5)	FW

More recommendations

Managers and Directors: Enzymatica AB

Manager	Title	Age	Since
Sana Alajmovic CEO	Chief Executive Officer	-	31/01/2026
Holger Lembrér DFI	Director of Finance/CFO	-	12/04/2026
Bjarki Stefánsson CTO	Chief Tech/Sci/R&D Officer	-	26/08/2026

Director	Title	Age	Since
Gudmundur Palmason CHM	Chairman	58	14/02/2016
Bengt Baron CHM	Chairman	64	18/12/2016
Mats K. Andersson BRD	Director/Board Member	71	18/12/2016

More insiders

Enzymatica AB (publ) is a Sweden-based life science company that develops and sells medical devices for infection-related diseases. The Company deals with research, development and sales of products based on enzyme technology and related activities. Enzymatica AB (publ) develops solutions that support the body's own defenses against virus, irritants and microorganisms. The Company offers products which are based on a barrier technology, includes marine enzymes. Enzymatica AB (publ) focuses on product development based on the tested and patented barrier technology used in the common cold product ColdZyme, a mouth spray that protects against colds, can help shorten the duration of the cold if used in the early stages of infection, relieves cold symptoms, and soothes sore throats.

Employees

Sector

Pharmaceuticals

Calendar

10-29 Earnings release - Q3 2026

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	420M 373M 349M 316M 597M 40.48B 601M 4.19B 1.63B 20.65B 1.58B 1.54B 66.39B	P/E 2024	-5.73x	P/E 2025	-8.89x
Enterprise Value	388M 344M 322M 292M 551M 37.39B 555M 3.87B 1.5B 19.07B 1.46B 1.42B 61.31B	EV / Sales 2024	5.88x	EV / Sales 2025	7.96x
Free-Float	56.66%	Yield 2024 *	-	Yield 2025	-

09-02	Enzymatica CEO buys additional shares	FW
09-01	Enzymatica CEO buys 33 384 shares	FW
08-27	Enzymatica expands group management with two executives	FW
08-27	Enzymatica AB Announces Appointment of Bjarki Stefánsson as Chief Scientist and Head of Production Iceland	CI
07-20	Enzymatica CFO Holger Lembrér buys shares for 110,000 kronor	FW
07-16	Enzymatica AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-16	Enzymatica cut revenue, but the loss also narrowed	FW
06-24	Enzymatica AB Provides Update On The Evidence Base For Coldzyme And PLOS ONE Expression Of Concern Regarding Berlin II Article	CI
06-24	Scientific paper on Enzymatica's Berlin II study receives an Expression of Concern, update	FW
06-23	Study of Enzymatica's cold spray Coldzyme gets a warning flag	FW
06-09	Enzymatica AB Announces Appointment of Joakim Tingström Nordin as Nordic Marketing and Sales Director, Effective August 2026	CI
06-09	Enzymatica appoints new Head of Marketing and Sales to drive Coldzyme growth in the Nordics	FW
04-28	Enzymatica Q1 operating loss narrows to SEK 13.6 million	RE

09-28	Notice of Extraordinary General Meeting in Enzymatica AB (publ)	AQ
08-27	Enzymatica strengthens its management team with commercial and scientific expertise	AQ
07-16	Quarterly report Q2/2026 Continued focus on international expansion and a stronger organization	AQ
06-24	The evidence base for ColdZyme remains unchanged – PLOS ONE notice concerns the presentation of the Berlin II article, not the evidence base for ColdZyme	AQ
06-09	Enzymatica appoints Marketing and Sales Director to accelerate ColdZyme’s continued growth in the Nordics	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENZYMATICA AB	+2.32%	+3.00%	-	-	42.09M
ELI LILLY AND COMPANY	+1.26%	-2.29%	+36.97%	+104.79%	1,032B
JOHNSON & JOHNSON	+0.73%	-4.78%	+35.41%	+61.62%	614B
ABBVIE INC.	+0.35%	+1.29%	+15.86%	+79.90%	471B
MERCK & CO., INC.	+1.72%	-4.92%	+59.84%	+36.64%	350B
ROCHE HOLDING AG	+1.63%	+1.80%	+23.19%	+41.68%	337B
NOVARTIS AG	+1.27%	-1.08%	+12.84%	+34.64%	268B
ASTRAZENECA PLC	+0.28%	-2.39%	-6.20%	+10.42%	246B
AMGEN INC.	-0.09%	-4.97%	+36.88%	+50.52%	218B
GILEAD SCIENCES, INC.	-0.28%	-4.66%	+26.99%	+92.98%	179B
Average	+0.80%	-3.39%	+26.86%	+57.02%	412.76B
Weighted average by Cap.	+0.66%	-3.18%	+29.85%	+67.28%

	2024	2025
Net sales	45.58M 40.46M 37.86M 34.32M 64.81M 4.39B 65.28M 455M 177M 2.24B 171M 167M 7.21B	53.9M 47.85M 44.78M 40.59M 76.65M 5.2B 77.21M 538M 209M 2.65B 202M 198M 8.52B
Net income	-53.18M -47.21M -44.18M -40.04M -75.62M -5.13B -76.17M -531M -206M -2.62B -200M -195M -8.41B	-51.89M -46.06M -43.11M -39.07M -73.79M -5B -74.32M -518M -201M -2.55B -195M -191M -8.2B
Net Debt	-73.01M -64.81M -60.65M -54.97M -104M -7.04B -105M -728M -283M -3.59B -274M -268M -11.54B	-32.11M -28.5M -26.68M -24.18M -45.66M -3.1B -45.99M -320M -125M -1.58B -121M -118M -5.08B

Enzymatica AB Share Price Nasdaq Stockholm

Stocks

SE0003943620

Pharmaceuticals

Valuation: Enzymatica AB

Latest news: Enzymatica AB

Analysts' recommendations: Enzymatica AB

Press Releases: Enzymatica AB

Quotes and Performance

Managers and Directors: Enzymatica AB

Other Pharmaceuticals

Financials

Company Profile